Rituximab for immune hemolytic anemia following T- and B-Cell-depleted hematopoietic stem cell transplantation.
The treatment of immune-mediated hemolytic anemia (IHA) complicating hematopoietic stem cell transplantation (HSCT) is often unsatisfactory. We report a case of IHA which occurred after T- and B-cell depleted unrelated donor HSCT carried out for mucopolysaccharidosis type I-H (Hurler syndrome) which was successfully treated with anti-CD20+ monoclonal antibody
Corti
P
P
Centro Trapianto di Midollo Osseo, Clinica Pediatrica dell'Università di Milano-Bicocca, Italia.
Bonanomi
S
S
Vallinoto
C
C
Balduzzi
A
A
Uderzo
C
C
Cazzaniga
G
G
Gaipa
G
G
Dassi
M
M
Perseghin
P
P
Rovelli
A
A
D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy* / Q000209:etiology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D018941:Antigens, CD19 / Q000097:blood; D001402:B-Lymphocytes / Q000166:cytology; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007223:Infant; D008212:Lymphocyte Depletion / Q000009:adverse effects*; D008059:Mucopolysaccharidosis I / Q000150:complications / Q000628:therapy; D000069283:Rituximab; D013601:T-Lymphocytes; D018183:Transplantation Chimera; D014184:Transplantation, Homologous / Q000009:adverse effects; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018941:Antigens, CD19; D006454:Hemoglobins; D000069283:Rituximab